The factory area of Zhongnuo Taizhou Company covers a total area of 115,533.3 square meters (equivalent to 173.3 Chinese mu). It is planned to comprise 1 comprehensive office building, 1 GSP-compliant warehouse, 1 high-rise automated warehouse, 1 power workshop and 5 production workshops, with a total planned construction area of approximately 140,000 square meters. With an investment of 250 million yuan, the Phase I project has completed the construction of a comprehensive preparation workshop for health food, a power workshop, warehouses, an office building, as well as supporting public utilities including sewage treatment systems, water supply, power supply and steam supply. The project was officially put into production in February 2017.

In terms of the company’s management organizational structure, it has established eight departments, namely the General Office, Production Department, Quality Department, R&D Department, Business Department, Finance Department, EHS (Environment, Health and Safety) Department and Procurement Department. The number of regular employees currently stands at 178, with a target of reaching 300 by 2019.

The completed comprehensive preparation workshop is equipped with production lines for solid preparations, soft capsules and oral liquids of oral health food, with a designed annual capacity of 1.5 billion tablets (grains/bags), 1 billion soft capsules and 50 million bottles of oral liquids. The laboratory ranks among the largest-scale and most advanced enterprise testing centers in the health food industry of Jiangsu Province.At present, the company has invested 20 million yuan in constructing a pilot production line for medical food, which is scheduled to obtain medical food certification in 2019. An investment of 180 million yuan is planned for 2019 to build a production workshop for Guoweikang VC lozenges with an annual capacity of 5–10 billion tablets. In the future, the company will also develop large health industry projects such as characteristic traditional Chinese medicine.

After obtaining its first production license in February 2017, the company has invested substantial human and material resources to accelerate the progress of product R&D, approval and certification. Up to now, a total of 31 products have obtained product filing numbers, 40 products have been granted production licenses, and 20 products are currently in the R&D and approval phase. In 2019, 25 products will be initiated and developed as new projects.

Products that have obtained production licenses include: CSPC Guoweikang Vitamin C Lozenges, Fulingzhibao Broken Ganoderma Lucidum Spore Powder, CSPC Ganoderma Green Tea Selenium-Enriched Yeast Capsules, Future Path Weili Oral Liquid, CSPC Natural VE Coenzyme Q10 Soft Capsules, Weishilai Banglide Tablets, CSPC Glucosamine Chondroitin Sulfate Vitamin D3 Calcium Tablets, Guoweilai VE VC Carotene Lozenges, Guoweikang Vitamin C Lozenges, CSPC Zunhong Soft Capsules, CSPC Propolis Lycopene Vitamin E Selenium-Enriched Yeast Soft Capsules, Future Path Yili Oral Liquid, CSPC Shili Capsules, Probiotic Series (solid beverages), Protein Solid Beverages, Gummy Candies, Compressed Candies, Guoweikang Multivitamin Calcium Iron Zinc Tablets, Guoweikang β-Carotene Vitamin C Lozenges, Guoweikang Selenium Tablets, Zishuai Multivitamin Chewable Tablets, Guoweikang Multivitamin Mineral Tablets, Guoweikang B-Complex Vitamin Lozenges, Guoweikang Calcium Vitamin D Soft Capsules, and CSPC Guoweikang Vitamin E Soft Capsules, etc.

While satisfying the domestic sales business of the group, the company has actively expanded sales channels and carried out OEM processing and foreign trade export processing services. It has established OEM cooperation with a number of enterprises, and various types of amino acid tablets and mineral tablets have been exported to the UK.